DSP's Boston acquisition in line with Japanese pharma's shift to oncology
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) liked the product so much they bought the company. But while an initial March 2011 option agreement with Boston Biomedical for an oncology candidate may have led to DSP acquiring the private US firm, the deal is also very much in line with similar moves by larger pharma companies in Japan.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.